Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crizanlizumab for Tissue Oxygen Supply Demand Matching in Sickle Cell Anemia
NCT05469828Phase 2Not yet recruiting
- Sponsor
- Children's Hospital Los Angeles
- Start
- Jul 2024
- Primary completion
- Jul 2028
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of crizanlizumab in sickle cell anemia (SCA), sponsored by Children's Hospital Los Angeles. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
crizanlizumab
03
Conditions
sickle cell anemia (SCA)
Beyond the preview
Go deeper on NCT05469828.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05469828.